Conformis Announces Bart Lagae as VP, International Sales & Marketing; Inducement Grant Reported
November 09 2020 - 3:30PM
Conformis, Inc. (NASDAQ:CFMS) announced today that the Company
has appointed Bart Lagae as its new VP, International
Sales & Marketing.
“We are pleased to announce that Bart Lagae has joined
our team as VP, International Sales & Marketing. Bart brings a
wealth of international experience and significant expertise in
building brands, developing and managing sales channels and market
expansion,” said Mark Augusti, President and Chief Executive
Officer. “I look forward to the contributions Bart will make
as a member of Conformis’ team.”
Bart Lagae
Bart Lagae is an executive with more than 30 years of
experience in orthopedic sales management and global marketing, and
has a track record of developing and successfully driving product
pipeline and business unit growth.
Most recently, Mr. Lagae served as Senior Director, Global
Marketing–Knees at Zimmer Biomet, where he worked for 5 years and
managed Partial, Primary, and Revision Knee teams and was
responsible for product strategy, portfolio, positioning and
business pipeline, and led marketing activities for new product
introductions. Immediately prior to Zimmer
Biomet, Mr. Lagae spent over 10 years
at Biomet where he progressed from Sales Representative
to Director, Product Management Partial Knees–Global.
Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
In connection with the hiring of Mr. Lagae,
Conformis' Board of Directors granted to Mr. Lagae a
restricted stock unit award of 75,000 shares
of Conformis' common stock. The restricted stock
unit award is expected to be granted on November 9,
2020 as an inducement material to Mr. Lagae’s acceptance
of employment with Conformis in accordance with Nasdaq
Listing Rule 5635(c)(4). The restricted stock unit award
vests over four years, with 25% of the total number of shares
underlying the award vesting on each one-year anniversary of the
grant date, subject to Mr. Lagae’s continued service as an
employee of Conformis through the applicable vesting
dates.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient's unique anatomy. Conformis offers a broad line
of sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals and ambulatory surgical
centers. In clinical studies, the Conformis iTotal
CR knee replacement system demonstrated superior clinical outcomes,
including better function and greater patient satisfaction,
compared to traditional, off-the-shelf
implants. Conformis owns or exclusively in-licenses
issued patents and pending patent applications that cover
personalized implants and patient-specific instrumentation for all
major joints.
For more information, visit www.conformis.com. To
receive future releases in e-mail alerts, sign up
at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, the anticipated timing of our product
launches, and our financial position and results, total revenue,
product revenue, gross margin, operations and growth, as well as
other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "project," "should,"
"target," "will," or "would" or the negative of these terms or
other and similar expressions are intended to identify
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make as a result of a variety of
risks and uncertainties; risks related to our estimates and
expectations regarding our revenue, gross margin, expenses, revenue
growth and other results of operations, and the other risks and
uncertainties described in the "Risk Factors" sections of our
public filings with the U.S. Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent our views as of the date hereof. We
anticipate that subsequent events and developments may cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date
hereof.
CONTACT:
Investor contact
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2024 to May 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From May 2023 to May 2024